-
Mashup Score: 65
/PRNewswire/ — GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Radiotherapy and Oncology on LinkedIn: November 2024 - 4 month(s) ago
🎉 Introducing the Radiotherapy & Oncology (Green Journal) on LinkedIn! 🎉 We’re excited to bring our leading research and insights to LinkedIn for the very…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet-
RT @RO_GreenJournal: 🌠We have also launched a LinkedIn page. Please follow the link for our first post: https://t.co/GGuXpqayHt
-
-
Mashup Score: 30Faire un don contre le cancer | Gustave Roussy - 1 year(s) ago
La lutte contre le cancer est un enjeu majeur de santé publique. Le cancer est la 1ère cause de mortalité en France. Chaque année, cette maladie est responsable de 157 400 décès et touche 382 000 personnes.Premier centre de lutte contre le cancer en Europe, Gustave Roussy et sa Fondation sont habilités à recevoir des dons et legs.Grâce à votre générosité, les progrès de la recherche aux bénéfices des patients d’aujourd’hui sont significativement accélérés et de tous ceux qui seront touchés demain.
Source: www.gustaveroussy.frCategories: General Medicine News, Hem/OncsTweet-
Pas dispo demain pour le @semideparis alors j'ai fait ma course dans mon coin ce matin, mais toujours dans l'équipe @GustaveRoussy ! Pour donner à Gustave Roussy pour soutenir la recherche contre le cancer : https://t.co/ZBl2PVW998 https://t.co/22AKTOASzr
-
-
Mashup Score: 10Donate to Gustave Roussy | Gustave Roussy - 1 year(s) ago
Donate to Gustave RoussyThe fight against cancer is a major public health issue.Cancer is the leading cause of death in France.Each year, cancer is responsible for 157,400 deaths and affects 382,000 people in France.Gustave Roussy and its Foundation are authorized to receive donations and legacies to support the research led by our experts and the improvement of the quality of life of our patients.Gustave Roussy would not be in the top 5 cancer centers in the world without the tremendous capacity to innovate that generosity allows.Philanthropy has a major role to play in leveraging the French
Source: www.gustaveroussy.frCategories: General Medicine News, Hem/OncsTweet-
Couldn't make it tomorrow for @semideparis, so I did my half marathon on my own today, as part of Team @GustaveRoussy Donate to Gustave Roussy for Cancer Research! https://t.co/7JKtE1gjsq https://t.co/GIerwIrTr9
-
-
Mashup Score: 57Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses - 1 year(s) ago
A single institution retrospective study suggested that head and neck squamous cell cancer (HNSCC) patients receiving radiotherapy (RT) during “dark” …
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Following @olgunelicin's work suggesting efficacy/toxicity of #radiotherapy for HN Cancer was higher in winter, we looked in MACH-NC/MARCH databases & 🥁🥁🥁 Nothing! Same effect of CT/RT in Winter vs Summer. Not surprising but good to show. full text: https://t.co/yE4wUmgX2y https://t.co/chBOSg3iMw
-
-
Mashup Score: 15
In a multicenter RCT (n = 78), radiation to high-risk asymptomatic bone metastases ⬇ skeletal-related events and prolonged OS.
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Hot off the press at @JCO_ASCO: prophylactic #radiotherapy for asymptomatic bone mets RCT by @ErinGillespieMD et al: ✅decreased skeletal event with RT (1.6% vs 29%) ✅Improved OS ✅RCT ❌small sample, mostly single center, various tumors Full paper: https://t.co/JKC3Q5IbKq https://t.co/eJ9eMlE3Vq
-
-
Mashup Score: 1Please wait whilst we redirect you - 2 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Our latest meta-analysis on #chemoradiation in nasopharyngeal cancer out in @TheLancetOncol Huge collaborative work. ✅ 28 trials, 8.000+ pts, 7.6y FU ✅ more chemo (ind+conc or conc+adj) ➡️superior (OS/PFS) to CRT alone but more tox Free 50day link: https://t.co/BtRJDZERRZ https://t.co/v2v5MsinnV
-
-
Mashup Score: 1Is single fraction the future of stereotactic body radiation therapy (SBRT)? A critical appraisal of the current literature - 2 year(s) ago
For several years, radiotherapy (RT) has increasingly evolved towards hypofractionation, on the basis of both radiobiological rationale and the technical possibility of safely delivering higher doses per fraction. Hypofractionation has added advantages in terms of patient convenience and faster patient turnover in RT departments. Moderate or severe hypofractionation, including stereotactic body…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Is single fraction the future of stereotactic #radiotherapy? My colleague @MarioTerlizziFR and others at @GustaveRoussy have tried to identify pros/cons & perspectives. Full text #OpenAccess at @ctRO_journal: https://t.co/hWwK2nfB3Y #radonc #sbrt https://t.co/iJUs7DYjcP
-
-
Mashup Score: 0
Radiation therapy (RT) combined with hormonal therapy is a standard treatment for intermediate- and high-risk prostate cancers [1,2,3]. Three randomized trials have evaluated the role of prostate brachytherapy boost, and one of several external beam radiation boost studies recently examined the benefits of intraprostatic focal boost [4,5,6,7]. They have shown that dose escalation (DE) improves…
Source: Radiotherapy and OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Outcomes following high dose rate #brachytherapy boost for high/intermediate risk #ProstateCancer. Our report shows high efficacy (85% bPFS at 5 years in high risk patients) with low toxicity (HDR better than seeds?). In press @RadiotherapyOn1 https://t.co/Z8J7ZjJYcC https://t.co/tDfCNtlo3p
-
-
Mashup Score: 0
Magnetic resonance-guided radiation therapy (MRgRT) utilization is rapidly expanding worldwide, driven by advanced capabilities including continuous i…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thanks Drew for the highlight. Full text here: https://t.co/nSg3L1bmcn And remember to submit your research to @ctRO_journal, the #openaccess @ESTRO_RT journal. Impact Factor 4.7 ! submit here: https://t.co/N7lWPM7JcA https://t.co/ObHr7l8jpH
-
GORTEC announces that the NIVOPOSTOP study (NCT03576417) met its primary endpoint of Disease-Free survival (DFS) across all comers high risk resected HNSCC. Combined with KN689 this represents the 2nd positive IO trial in the postop setting. https://t.co/tuRnnvf5Pc https://t.co/CrsKKBFU7W